I am/have/had
I am looking for
Advanced Filters
Found 1 clinical trials
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC
The study primary endpoints are PFS per RECIST v. 1.1 and safety. KEAP1/NRF2 mutation status (for eligibility) and STK11/LKB1 status (for stratification) will be determined by next generation sequencing. A commercial liquid biopsy (circulating tumor DNA) NGS test will be provided to study participants free of charge.
pembrolizumab
systemic therapy
BRAF
proto-oncogene tyrosine-protein kinase ros
vitamin b12 level
- 0 views
- 16 Feb, 2024
- 28 locations